Tauriga Sciences, Inc. Appoints Matthew A. Shaw as Member of Its Corporate Advisory Board

Rhea-AI Summary

Tauriga Sciences, Inc. (TAUG) has appointed Matthew A. Shaw to its Corporate Advisory Board. Shaw, who currently leads Mergers & Acquisitions Tax for Nestlé, will provide strategic advisory focusing on revenue growth and market expansion. He brings extensive experience from KPMG and Nestlé, having overseen over $30 billion in transactions. Tauriga specializes in life sciences, primarily in CBD and CBG products, including their Tauri-Gum™ line. The company also pursues pharmaceutical development for nausea related to chemotherapy, having filed a U.S. Non-Provisional Patent Application.

Positive

• Appointment of Matthew A. Shaw adds significant expertise to the advisory board.
• Shaw's experience in M&A and tax strategies may facilitate revenue growth and market expansion.
• Tauriga has a diverse product line, enhancing its market presence.

Negative

• Shaw's relationship with the CEO may raise concerns about potential nepotism.
• Dependence on Shaw's expertise may create a gap if he leaves or is unable to contribute.

NEW YORK, NY, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has appointed Mr. Matthew A. Shaw to its Corporate Advisory Board.  Currently, Matthew A. Shaw serves as Head of Mergers & Acquisitions/Tax (“M&A Tax”) for the U.S. businesses of Nestlé, the world’s largest food and beverage company.

In joining Tauriga’s Corporate Advisory Board, his main focus will be to help the Company in a general strategic advisory role in evaluating opportunities to grow revenue and expand market opportunities.  Mr. Matthew A. Shaw is the brother of our Company’s CEO, whose valuable business acumen should serve the Company well in his capacity as an advisor.

Personal Bio – Mr. Matthew A. Shaw

Matthew A. Shaw, J.D., LL.M., draws upon nearly fifteen years of experience providing strategic solutions to multi-billion-dollar corporate tax issues for Fortune 100 companies. Mr. Shaw obtained his Bachelor of Science degree from Cornell University, and law degree from William and Mary School of Law, where he served on the editorial board of the William & Mary Law Review.  Thereafter he graduated, with distinction, from The Georgetown University Law Center, earning a Master of Laws in Taxation.  Mr. Shaw served as an advisor in the M&A Tax group of KPMG’s Washington National Tax Office for over a decade, where his practice focused on acquisitions and divestitures, including many multi-billion-dollar public spin-off transactions, internal restructuring transactions, debt and equity offerings, loss monetization transactions, and consolidated return matters.  Mr. Shaw left KPMG as a Managing Director in 2018 to join Nestlé USA, where he currently serves as Head of M&A Tax and Assistant General Tax Counsel.  While at Nestlé, he has overseen the tax aspects of more than $30 billion of acquisitions and divestitures, including due diligence, structuring, funding, legal documents, and integration.  He speaks in professional forums such as the D.C. Bar and Tax Executives Institute, and has published several articles, including in The Journal of Corporate Taxation, and in the BNA Daily Tax Report. Outside of professional activities, Matt is an avid chess fan and carries a master level rating (albeit provisional) at the USCF.  

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com 
Cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com 
E-Commerce Website: www.taurigum.com

FAQ

Who is Matthew A. Shaw and what is his role at Tauriga Sciences?

Matthew A. Shaw has been appointed to the Corporate Advisory Board of Tauriga Sciences. He is currently Head of Mergers & Acquisitions Tax for Nestlé.

What impact does Matthew A. Shaw's appointment have on Tauriga Sciences?

Shaw's appointment is expected to enhance strategic advisory capabilities, particularly in growing revenue and expanding market opportunities.

What product lines does Tauriga Sciences focus on?

Tauriga Sciences specializes in CBD and CBG products, particularly its Tauri-Gum™ line.

What are Tauriga Sciences' future plans in pharmaceutical development?

Tauriga is developing a pharmaceutical-grade version of Tauri-Gum™ aimed at nausea regulation for chemotherapy patients.

What is the significance of the U.S. Non-Provisional Patent Application filed by Tauriga Sciences?

The patent application, converted from a provisional filing, covers medicated CBD compositions, which could enhance the company's product offerings.